Introduction

When a pharmaceutical innovator faces simultaneous generic challenges to a blockbuster oncology-supportive drug, the litigation response can define market exclusivity for years. In May 2025, Pharmacosmos filed three parallel Hatch-Waxman patent infringement actions in the U.S. District Court for the District of New Jersey against Hetero Labs Limited, Teva Pharmaceuticals, and Dr. Reddy’s Laboratories—all targeting generic versions of COSELA® (trilaciclib), a first-in-class myeloprotective agent used to decrease chemotherapy-induced myelosuppression.

Case No. 2:25-cv-03945, Pharmacosmos v. Hetero Labs, Ltd., was closed after just 244 days when the three related actions were consolidated into a single lead docket for all pretrial purposes. The consolidation—stipulated by all parties and ordered by the court—signals a coordinated, high-stakes defense of two key patents covering trilaciclib technology. For patent litigators, ANDA practitioners, and pharmaceutical R&D teams, this case offers instructive lessons in multi-defendant litigation strategy, pretrial efficiency, and the protection of specialty drug IP portfolios.

Primary Keyword: Trilaciclib patent infringement | COSELA® ANDA litigation

Aperçu du dossier

Les parties

Les brevets en cause

This litigation involves two key patents protecting COSELA® (trilaciclib), which is indicated to address myelosuppressive effects of chemotherapy. The patents cover aspects of trilaciclib technology.

• • U.S. Patent No. 12,168,666 B2 — Covers formulation or method-of-use claims related to trilaciclib’s therapeutic application.
• • U.S. Patent No. 11,529,352 B2 — An earlier patent in the same trilaciclib technology family, likely covering composition or earlier-stage clinical use claims.

Les produits incriminés

Each defendant filed an Abbreviated New Drug Application (ANDA) seeking FDA approval for a generic version of COSELA® (trilaciclib) for injection, intravenous drug product—triggering the statutory 30-month stay under the Hatch-Waxman Act upon Pharmacosmos’s timely patent infringement lawsuit.

Représentation juridique

Pharmacosmos was represented by Gibbons PC, with attorneys Abigail Struthers, Christine A. Gaddis, David DeNuyl, David E. DeLorenzzi, Jeremy Cobb, and Jerrit Yang leading the matter. Hetero Labs retained Greenberg Traurig PA, with Douglas Robert Weider and Giancarlo Scaccia as counsel of record.

Chronologie du litige et historique de la procédure

Pharmacosmos filed three related Hatch-Waxman actions in rapid succession in the District of New Jersey—a preferred venue for pharmaceutical patent litigation given its experienced patent judiciary and proximity to major pharma operations. Cases 2:25-cv-03218 (vs. Teva), 2:25-cv-03945 (vs. Hetero Labs), and 2:25-cv-03967 (vs. Dr. Reddy’s) were all assigned to Judge Julien Xavier Neals (JXN) with Magistrate Judge André M. Espinosa (AME).

The 244-day duration to closure reflects not a final adjudication on the merits, but an efficient procedural consolidation. All parties stipulated to combining the three actions for all pretrial purposes under the lead docket, Civil Action No. 2:25-cv-03218, pursuant to Federal Rule of Civil Procedure 42. The parties expressly reserved rights to request joint or separate trials under FRCP 42(b), preserving strategic flexibility for trial-stage proceedings.

Le verdict et l'analyse juridique

Résultat

Case No. 2:25-cv-03945 was closed by court-ordered consolidation, not by final judgment, dismissal, or settlement. The action’s pretrial proceedings are now unified under the lead case (2:25-cv-03218) against Teva. No damages have been adjudicated, no injunction has been issued, and no infringement determination has been rendered at this stage. The 30-month stay protections under Hatch-Waxman likely remain operative pending final resolution.

Consolidation Analysis: Strategic and Legal Significance

The consolidation of three parallel ANDA cases involving identical patents and the same branded drug—under FRCP 42—is a textbook efficiency mechanism in multi-defendant Hatch-Waxman litigation. Key legal implications include:

• Judicial Economy: A single claim construction ruling will bind all three generic challengers simultaneously. This benefits Pharmacosmos by creating uniform patent scope determinations, while also allowing the generics to align invalidity arguments and share discovery burdens.
• Coordinated Defense Risk: For Hetero Labs, Teva, and Dr. Reddy’s, consolidation creates both opportunity and risk. While joint discovery reduces individual cost, coordinated defenses on invalidity (e.g., obviousness, prior art) may strengthen collective arguments. Conversely, if one defendant’s invalidity arguments fail, all are affected by shared claim construction rulings.
• Trial Severance Option Preserved: Crucially, the stipulation preserves each party’s right to seek separate trials under FRCP 42(b). This strategic reservation matters for damages calculations, willfulness arguments, and defendant-specific equitable defenses that may vary across the three generics manufacturers.

Patent Validity and Infringement Framework

Under Hatch-Waxman, the filing of an ANDA with a Paragraph IV certification constitutes a constructive act of infringement under 35 U.S.C. § 271(e)(2). Pharmacosmos need only demonstrate that the defendants’ proposed generic products would, if approved, infringe the asserted claims of U.S. Patent Nos. 12,168,666 and 11,529,352.

Expected defense theories will likely include:

• • Obviousness challenges under 35 U.S.C. § 103, citing prior art in CDK4/6 inhibition or myeloprotection chemistry
• • Written description or enablement challenges under § 112 given the breadth of formulation or method claims
• • Non-infringement based on ANDA product specifications differing from claim limitations

Points stratégiques à retenir

• • For Patent Holders (Pharmacosmos model): Filing simultaneous actions on identical patents against all ANDA filers preserves the 30-month stay for each and maximizes leverage for consolidated or individual settlements. Venue in D.N.J. offers access to judges experienced in Hatch-Waxman mechanics and complex pharmaceutical claim construction.
• • For Generic Defendants (Hetero Labs, Teva, Dr. Reddy’s model): Early consolidation agreements can reduce pretrial costs substantially, but defendants must carefully assess whether joint claim construction positions align with each company’s ANDA formulation specifics. Preserving the right to separate trials under FRCP 42(b) is essential where individual defendant circumstances (e.g., commercial launch dates, damages exposure) diverge.
• • For R&D and Regulatory Teams: The dual-patent protection strategy on COSELA® (covering both earlier composition claims and later application-specific patents) illustrates the value of layered IP portfolios for specialty biologics and injectables.

Implications pour l'industrie et la concurrence

COSELA® (trilaciclib) occupies a unique market position as the only FDA-approved myeloprotective agent, giving Pharmacosmos significant exclusivity leverage. The simultaneous ANDA filings by Hetero, Teva, and Dr. Reddy’s reflect aggressive generic interest in a product with substantial oncology-market commercial potential.

The consolidation outcome—while procedural—signals that the true patent contest is just beginning. Claim construction proceedings, Markman hearings, and potential summary judgment motions under the lead docket will set the substantive IP battleground. Licensing settlements with individual defendants (as is common in Hatch-Waxman disputes) remain a probable resolution pathway, particularly if Pharmacosmos achieves favorable early claim constructions.

For the broader specialty pharmaceutical sector, this case underscores how layered patent portfolios with staggered expiration dates—combined with decisive multi-defendant litigation—can extend effective market exclusivity well beyond any single patent’s term. R&D teams at generic manufacturers entering oncology-supportive care spaces should conduct rigorous Freedom to Operate (FTO) analyses across all family members before ANDA filing.

The case also reflects a continuing trend of New Jersey as the de facto Hatch-Waxman forum, given its concentration of pharmaceutical industry defendants, sophisticated patent bar, and judicial familiarity with the regulatory intersection of FDA and patent law.